Musharraf Navaid, MD
Hematology & Oncology · Greenville, NCNPI 1821061755
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.8% of the total across 186 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 12.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,278 and has fallen 90.3% since, to $220 in 2025.
Across 186 payments — averaging $18.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$411
- E.r. Squibb & Sons, L.L.C.$386
- Pfizer$354
- Astellas Pharma US Inc$255
- Merck$198
- Exelixis Inc.$166
- plus $2K from 32 others
Across 38 payments — averaging $4319.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seagen Inc.$153K
- Pfizer$6K
- AstraZeneca$5K
What the payments were for
- Food & beverage$3,18494%
- Education$2106%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 13 | $411 |
| E.r. Squibb & Sons, L.L.C. | 29 | $386 |
| Pfizer | 24 | $354 |
| Astellas Pharma US Inc | 6 | $255 |
| Merck | 14 | $198 |
| Exelixis Inc. | 9 | $166 |
| Lilly USA, LLC | 4 | $148 |
| Dendreon Pharmaceuticals LLC | 2 | $147 |
| Bristol Myers Squibb | 6 | $116 |
| Genentech USA, Inc. | 8 | $112 |
| Amgen | 7 | $111 |
| Eisai Inc. | 6 | $109 |
| Novartis | 6 | $100 |
| EMD Serono, Inc. | 7 | $85 |
| Bayer | 5 | $64 |
| Gilead | 3 | $62 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $60 |
| Sanofi | 4 | $59 |
| Jazz Pharmaceuticals Inc. | 3 | $51 |
| Johnson & Johnson | 3 | $47 |
| Shire North American Group Inc | 3 | $44 |
| AbbVie | 2 | $33 |
| Seagen Inc. | 2 | $31 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Tempus AI, Inc | 1 | $23 |
| Ipsen Biopharmaceuticals, Inc | 1 | $21 |
| Tesaro, Inc. | 1 | $19 |
| Tersera Therapeutics LLC | 1 | $19 |
| GSK | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Rigel Pharmaceuticals, Inc. | 1 | $15 |
| Dova Pharmaceuticals | 1 | $15 |
| BTG International Inc. | 1 | $15 |
| Servier Pharmaceuticals LLC | 1 | $15 |
| Karyopharm Therapeutics Inc. | 1 | $13 |
| Kyowa Kirin, Inc. | 1 | $11 |
| Incyte Corporation | 1 | $11 |
| Secura Bio, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,395 in reported general payments places this provider in the 60th percentile of 358 hematology & oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 65 | $1,367,100 |
| NubeqaDarolutamide | 74 | $781,620 |
| XtandiEnzalutamide | 29 | $418,538 |
| ErleadaApalutamide | 24 | $358,300 |
| OrgovyxRelugolix | 83 | $179,221 |
| Abiraterone Acetate | 112 | $142,243 |
| CreonLipase/Protease/Amylase | 37 | $86,573 |
| EliquisApixaban | 39 | $23,749 |
| XareltoRivaroxaban | 12 | $6,463 |
| Oxycodone Hcl | 126 | $2,562 |
| Gabapentin | 66 | $1,066 |
| Duloxetine Hcl | 48 | $1,047 |
| Morphine Sulfate ErMorphine Sulfate | 32 | $1,028 |
| Imatinib Mesylate | 18 | $956 |
| Hydrocortisone | 14 | $835 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $166 | $1,367,10065 claims |
| BayerNubeqa | $64 | $781,62074 claims |
| Astellas Pharma US IncXtandi | $255 | $418,53829 claims |
| Johnson & JohnsonErleada, Xarelto | $47 | $364,76336 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $24 | $179,22183 claims |
| AbbVieCreon | $33 | $86,57337 claims |
| PfizerEliquis | $354 | $23,74939 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 358 hematology & oncology providers in North Carolina.
Other hematology & oncology in Greenville
- Amit MehtaCary$4.3M
- Michael MorseDurham$2.6M
- Shelbi AtrashCharlotte$994K
- Phillip FebboDurham$749K
- Angela AlistarWinston Salem$509K
- Ravi PaluriWinston Salem$314K
- Matthew McKinneyDurham$277K
- Jared WeissChapel Hill$217K
- Joshua ZeidnerChapel Hill$208K
- Taewoong ChoiDurham$207K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.